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Abstract
Patients (n = 40) with hypercholesterolaemia (29 females), mean age 63 years, without
previous lipid lowering treatment,  were treated with atorvastatin 40 mg/day for 3
months.  Total  cholesterol  (TC),  low-density  lipoprotein  cholesterol  (LDL-C),  high-
density lipoprotein cholesterol (HDL-C), triglycerides (TG), LDL-C subfractions (large
LDL-C and small dense LDL-C particles), apolipoprotein A1 (apo A1), apolipoprotein
B (apo B),  apo B/apo A1 ratio,  atherogenic  index of  plasma (AIP),  haematological
parameters including mean platelet volume (MPV), and red cell distribution width
(RDW) and safety parameters (renal and hepatic function) were measured before and
after 12 weeks of atorvastatin treatment. Atorvastatin significantly reduced small dense
LDL (sdLDL) fraction 3–7 and apo B. There was a negative correlation of AIP with
buoyant LDL 1–2 (r = −0.35; p < 0.05) and positive with small dense LDL 3–7 (r = 0.52, p
< 0.001). Administration of atorvastatin 40 mg/day in patients with hypercholesterolae-
mia caused a shift in small dense LDL subfractions to large, buoyant subfractions. AIP
correlated  better  with  small  dense  LDL  than  apo  B  levels.  At  baseline,  a  strong
correlation between HDL-C, TG, small dense LDL-C, apo B, apo B/apo A1 and AIP with
MPV was found. After 12 weeks of treatment with atorvastatin, MPV and RDW values
underwent significant modification only in those patients displaying the strongest lipid-
lowering effect. Values of MPV and RDW seem to reflect a pro-atherogenic lipoprotein
profile mainly represented by the presence of small dense LDL-C. No serious atorvas-
tatin adverse events were noted.
Keywords: atorvastatin, small dense LDL, atherogenic dyslipidaemia, mean platelet
volume, red cell distribution width
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1. Introduction
Abnormal  lipid  metabolism preceding  overt  atherosclerosis  is  associated  with  increased
cardiovascular  risk.  In  atherogenic  dyslipidaemia,  the  lipoprotein  abnormalities  include
increased small dense LDL particles (sdLDL), elevations of VLDL and low HDL-cholesterol
usually occur together [1, 2]. Over the last two decades, it has been demonstrated that routine
measurement  of  total  cholesterol,  LDL-C and HDL-C fails  to  distinguish  all  lipoprotein
abnormalities  associated  with  cardiovascular  diseases  [3].  There  is  a  need  to  find  new
biomarkers  for  this.  By  contrast,  the  analysis  of  lipoprotein  subfractions  appears  more
important in assessing the risk of cardiovascular complications [4]. LDL-C remains the primary
focus for cardiovascular risk assessment and evaluation of pharmacologic effectiveness, but
not based on LDL targets instead on LDL lowering [5]. Yet, a large body of evidence indicates
that a narrow focus on LDL-C assessment and treatment alone is not the optimal strategy for
patient  care  [6].  Examining  individual  lipoprotein  subpopulations/subfractions  provides
opportunities for risk stratification, independent of commonly determined lipid parameters
[7].
2. Plasma atherogenic biomarkers
The term “lipid triad” has been introduced to describe a common form of dyslipidaemia,
characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased
HDL-cholesterol concentrations and the presence of sdLDL particles [8]. Apolipoprotein B
(apo B) is the major protein of all lipoproteins except for high-density lipoprotein. Estimation
of apo B reflects the total number of sdLDL particles. It is notable that LDL particles can vary
in size, cholesterol content and number, for a given concentration of LDL-C.
Haematological parameters, mainly red cell distribution width (RDW) and mean platelet
volume (MPV) have gained great interest in cardiovascular research. This has been reported
to be a strong and independent predictor of adverse cardiovascular outcomes in the general
population [9]. In the last few years, MPV, respected an effective marker of platelet activation,
has also created much interest in cardiovascular research. This stems from the fact that platelets
undergo a dramatic change in shape from quiescent discs to swollen spheres, with an increased
MPV, during the activation process. It is well-known that large platelets are more adhesive and
prone to aggregate than smaller ones [10], and elevated MPV values have been reported in
cardiovascular diseases [11]. “Another haematological parameter which seems to play a role
is RDW, a measure of the variability of red cell size. RDW has been reported to be a strong and
independent predictor of adverse cardiovascular outcomes in the general population” [12].
The aim of our study was to compare different methods in the evaluation of atherogenicity,
including that of the detailed lipid profile.
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3. Analytic system
Various methods have been developed such as gradient gel electrophoresis, ultracentrifuga-
tion, magnetic resonance spectroscopy, endothelial models for testing lipoprotein cytotoxicity
to identify atherogenic lipoproteins [13], but because of technical and financial limitations,
long-term analyses and high operating costs, the previously mentioned methods were used
primarily in basic research. Electrophoresis of plasma lipoproteins on the polyacrylamide gel
(PAG) Lipoprint LDL system is a new method, which has become a milestone in routine
laboratory analysis and in diagnosing disorders of lipoproteins, for the identification and
quantitative evaluation of lipoprotein subfractions, i.e., the atherogenic and non-atherogenic
lipoproteins [14]. The benefits of Lipoprint LDL method are in unique identification of an
atherogenic and non-atherogenic lipoprotein spectrum in case of hyperlipoproteinaemia with
the possibility of a better assessment of the adequacy of lipid-lowering interventions. Another
important aspect is to identify the atherogenic lipoprotein profile in patients with normolipi-
daemia after lipid-lowering therapy [15].
4. Cholesterol lowering, atherogenic biomarker alteration and therapy
Clinical trials with statins have demonstrated significant reductions in cardiovascular events.
Although the benefit of statin therapy has generally been ascribed to reduction in LDL-C, other
atherogenic classes of lipoproteins may be beneficially affected by statin therapy [16]. The
beneficial effects of atorvastatin treatment have been known for a long time although, the effect
of atorvastatin on other classes of atherogenic lipoproteins has not been well studied. Previous
studies, which were performed in limited trials of patients with atorvastatin 10 and 20 mg,
resulted in a shift from small to large atherogenic particles of low-density lipoprotein (LDL)
[17, 18]. We know that atorvastatin can improve lipoprotein metabolism, however, the
medication affects different aspects of lipoprotein metabolism.
Lipid lowering treatment changes the sizes and concentrations of subtype lipoproteins and
the values of some haematological parameters. There are more another favourable effects of
statins in regulation of coagulation, inflammation and vascular function instead reducing
LDL-C [19, 20]. Therefore, the influence of atorvastatin in decreasing cardiovascular risk could
be through reduction of MPV levels. The antiplatelet and anti-inflammatory effect of atorvas-
tatin could play a role in decreasing cardiovascular risk by reduction of MPV levels [21].
Patients with low HDL-C have significantly higher levels of MPV [22]. Likewise, the negative
association has been revealed between increased RDW and low HDL-C values evaluated in
large outpatient trials [23]. However, there are little data evaluating the association between
MPV, RDW and low-density lipoproteins values.
A further aim of the present survey was to identify the relationship between low-density
lipoprotein subfractions and haematologic parameters. The point of interest was to examine
whether MPV and RDW have predictive potential for plasma levels and composition of pro-
or anti-atherogenic lipoproteins. A cohort of 40 patients with hypercholesterolaemia (29
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females, mean age 62.9 ± 9 years), without previous hypolipidaemic treatment were enrolled.
The patients were treated with atorvastatin 40 mg/day for 12 weeks. There was documented
hypercholesterolaemia in 21 patients, combined with hyperlipoproteinaemia in 19 of those.
4.1. Study design
All participants signed informed content and went through a screening protocol which
included evaluation of their medical history, physical examination and testing for standard
haematologic and biochemical analysis. Exclusion criteria were a history of diabetes mellitus,
glomerular filtration rate less than 60 ml/min (estimated glomerular filtration rate using MDRD
equation [GFR] < 60 ml/min) and liver abnormalities (abnormal AST, ALT, history of hepat-
opathy or cirrhosis), history of acute myocardial infarction or stroke, hypothyroidism or
hyperthyroidism (abnormal TSH), cancer, history of pancreatitis, alcohol or drug abuse,
systemic connective tissue diseases, history of anaemia, red blood cell transfusion, supple-
mentation of iron, folate or stimulation of erythropoiesis. Patients were eligible to take part in
the study if they met the criteria of the National Cholesterol Education Program-Adult
Treatment Panel 3 (NCEP-ATP3) [24]. None of the patients involved in the study were treated
with a statin before, even though some already had a diagnosis of hypertension or ischaemic
heart disease. Physical and laboratory examinations were carried out after first, second and
third month of treatment. The study was approved by the local ethics committee of the
University Hospital in Bratislava and was conducted in accordance with the Declaration of
Helsinki.
4.2. Measurements
Blood samples were drawn from the cubital vein in the morning after 12 h fasting period.
Monitoring included laboratory screening (liver and renal function, glucose, electrolytes,
thyroid stimulating hormone), identification of plasma atherogenity—apolipoprotein B,
apolipoprotein A1, ratio apo B/apo A1 by immunoturbidimetric method (Roche, Germany)
and atherogenic index of plasma (AIP) using the formula log (triglycerides [TG]/high-density
lipoprotein cholesterol [HDL-C]).
The lipoprotein subpopulations—VLDL (very low-density lipoprotein), IDL (intermediate
density lipoprotein): IDL1, IDL2, IDL3 (the PAG method separates the intermediate-density
lipoprotein particles into three midbands MID-C, MID-B and MID-A on figures), LDL 1 to LDL
7 and HDL (high-density lipoprotein) were determined by the linear electrophoresis in
polyacrylamide gel (Quantimetrix Lipoprint LDL System and Quantimetrix, California, USA).
The type of lipoprotein spectrum was determined as non-atherogenic profile versus athero-
genic profile. LDL 1 and LDL 2 were classified as large particles (non-atherogenic) and LDL 3
to 7 as sdLDL particles (atherogenic).
Haematological variables (including MPV, RDW) before and after treatment were measured
by cell analysers (Sysmex Haematology Analyzer XP-2000i, Japan). The normal range of MPV
(fl) and RDW (%) in our laboratory was 7.8–11 and 10.0–15.2, respectively. The blood samples
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were collected in tripotassium EDTA tubes and time delay between sampling and data analysis
was strictly controlled to be less than 2 h.
4.3. Statistical analysis
GraphPad Prism 5 software for Windows was used. The D’Agostino Pearson test and Kolmo-
gorov-Smirnov test were used to verify the normal distribution of parameters in the cohort.
Continuous variables were expressed as mean ± SD or median and interquartile range. We
used Spearman’s and Pearson’s correlation analyses. For the 40 patients who were studied
before and after 3 months of atorvastatin treatment, unpaired t tests were performed to
compare apo A1, apo B, AIP and serum lipoproteins at baseline versus after 3 months of
treatment. The effect of 12 weeks treatment with atorvastatin on lipid and haematological
parameters was evaluated by using paired t test and Wilcoxon matched-pairs signed rank test.
A two-tailed probability level <0.05 was considered significant.
4.4. Results
Patients in the study were diagnosed with dyslipoproteinaemia, in which 52.5% patients (n =
21) was found isolated hypercholesterolaemia and the other patients (47.5%, n = 19) combined
with hyperlipidaemia. Isolated hypertriglyceridaemia was not detected. The baseline charac-
teristics of the participants are presented in Table 1. When structuring groups of patients
according to atherogenic and non-atherogenic lipoprotein profiles, hypercholesterolaemia
without the presence of sdLDL was found in 29 subjects (72.5%), atherogenic sdLDL in 11
persons (27.5%), whereas 42% of patients with combined hyperlipaemia (n = 8) and only 14%
of patients with isolated hypercholesterolaemia (n = 3) had atherogenic lipoprotein profile
phenotype. We also observed 35% (n = 14) of individuals with hyperlipoproteinaemia LDL 1,
2 with non-atherogenic lipoprotein profile phenotype.
Men Women
Number n (%) 11 (27.5%) 29 (72.5%)
Min–
max
Mean ± SD Min–
max
Mean ± SD
Age (years) 42–72 60 ± 9.0 47–85 63.6 ± 9.1
BMI (kg/m2) 23.2–
33.7
28.6 ± 3.1 20.8–39.1 26.7 ± 4.7
Waist (cm) 78–
108
94.6 ± 12.0 74.0–
113.0
87.2 ± 10.2
Smokers, n (%) 4 (36.4%) 4 (13.8%)
CAD, n (%) 2 (18.2%) 4 (13.8%)
Arterial hypertension, n (%) 8 (72.5%) 22 (75.9%)
Obesity, n (%) 3 (27.3%) 6 (20.7%)
BMI, body mass index; CAD, coronary artery disease; SD, standard deviation.
Table 1. Baseline characteristics of patients included in the study.
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AIP apo B apo A1 apo B/apo A1
LDL 1–2 −0.35
p < 0.05
0.54
p < 0.001
0.13
NS
0.358
p < 0.05
sdLDL 3–7 0.52
p < 0.001
0.64
p < 0.001
−0.23
NS
0.62
p < 0.001
HDL −0.75
p − 0.001
−0.43
p < 0.05
0.58
p < 0.001
−0.60
p < 0.001
IDL 1–3 0.14
NS
0.19
p < 0.05
−0.19
NS
0.18
NS
AIP, atherogenic index of plasma; apo, apolipoprotein; LDL, low-density lipoprotein; sdLDL, small dense low-density
lipoproteins; HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; NS, not significant.
Table 2. Correlation between subpopulations and AIP, apo B, apo A1 and apo B/apo A1.
Before treatment After treatment p
TC (mmol/l) 6.7 ± 1.0 4.6 ± 1.3 <0.001
TG (mmol/l) 1.8 ± 0.9 1.5 ± 1.0 <0.05
LDL-C (mmol/l) 4.3 ± 1.0 2.6 ± 0.9 <0.001
HDL-C (mmol/l) 1.4 ± 0.4 1.2 ± 0.3 <0.001
apo A1 (g/l) 1.68 ± 0.26 1.63 ± 0.25 NS
apo B (g/l) 1.00 ± 0.25 0.74 ± 0.22 <0.001
apo B/apo A1 0.59 ± 0.20 0.45 ± 0.16 <0.001
AIP 0.03 ± 0.30 0.03 ± 0.31 NS
Fasting glucose (mmol/l) 5.69 ± 1.31 5.69 ± 1.53 NS
hsCRP (mg/l) 3.20 ± 3.58 2.24 ± 2.65 <0.05
BMI (kg/m2) 27.2 ± 4.3 26.9 ± 4.3 <0.05
Waist (cm) 89.2 ± 11.1 88.7 ± 11.1 NS
SBP (mmHg) 131.2 ± 12.4 126.6 ± 9.4 <0.05
DBP (mmHg) 76.4 ± 8.8 72.9 ± 9.3 <0.05
VLDL (mmol/l) 0.95 ± 0.36 0.67 ± 0.32 <0.001
IDL 1–3 (mmol/l) 1.63 ± 0.38 1.16 ± 0.33 <0.001
LDL 1–2 (mmol/l) 2.50 ± 0.76 1.55 ± 0.65 <0.001
sdLDL 3–7 (mmol/l) 0.22 ± 0.32 0.09 ± 0.16 <0.001
TC, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; sdLDL, small dense low-density lipoproteins;
HDL, high-density lipoprotein; apo A1, apolipoprotein A1; apo B, apolipoprotein B; AIP, atherogenic index of plasma;
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; hsCRP, highly sensitivity C-reactive
protein; VLDL, very low-density lipoprotein; IDL, intermediate density lipoprotein.
Table 3. Effect of atorvastatin on lipids, apolipoproteins, fasting glucose, hsCRP, AIP and other parameters.
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We observed a positive correlation between apo B and sdLDL 3–7 (r = 0.64, p < 0.001), and with
LDL 1–2 (r = 0.54, p < 0.001). AIP showed a negative correlation with LDL 1–2 (r = −0.35, p <
0.05) and was positively correlated with sdLDL 3–7 (r = 0.52, p < 0.001; Table 2). There was a
non-significant change of the atherogenic index of plasma (0.03 ± 0.30 versus 0.03 ± 0.31, p =
0.142), significant decrease in high-sensitivity C-reactive protein (hsCRP) (3.20 ± 3.58 versus
2.24 ± 2.65 mg/l, p < 0.05) and body mass index (BMI) (27.2 ± 4.3 versus 26.9 ± 4.3 kg/m2, p <
0.05; Table 3).
Figure 1. Distribution of lipoproteins using polyacrylamide gel method before (A) and after (B) treatment with atorvas-
tatin 40 mg. Atherogenic lipoproteins are present despite treatment (MID-C is IDL-1, MID-B is IDL-2 and MID-A is
IDL-3).
Figure 2. Reduction of lipoprotein subpopulations after treatment (B) with atorvastatin 40 mg compared with baseline
lipid lipoprotein profile (A). There is fall in the atherogenic LDL 3–7 fraction after treatment (MID-C is IDL-1, MID-B is
IDL-2 and MID-A is IDL-3).
Despite lipid-lowering therapy and normal values of lipids, the Lipoprint LDL method
revealed presence of sdLDL (Figure 1). Atorvastatin significantly reduced the presence of
sdLDL 3–7 (0.22 ± 0.37 versus 0.09 ± 0.16 mmol/l, p < 0.001), as well as other subpopulations of
Influence of Atorvastatin on Plasma Atherogenic Biomarkers
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lipoproteins (LDL 1–2, VLDL, IDL 1–3; Figure 2). Atorvastatin 40 mg had little effect on the
initial subfractions LDL 1 and LDL 2 (Figure 3). The proportion of buoyant and sdLDL at
baseline was 11.36 mmol/l (p < 0.001) and after treatment 17.22 mmol/l (p < 0.001).
Figure 3. Effect of atorvastatin 40 mg on hyperbetalipoproteinaemia before (A) and after treatment (B). There were no
changes in lipoprotein profile after treatment (MID-C is IDL-1, MID-B is IDL-2 and MID-A is IDL-3).
Haematological parameters Before treatment
Mean ± SD/Median [IOR]
After treatment
Mean ± SD/Median [IOR]
P
RBC (1012/l) 4.16 [3.9–4.7] 4.12 [3.9—4.69] NS
Haemoglobin (g/l) 143.0 [139.0–148.8] 143.0 [137.3–147.8] NS
MCV (fl) 90.45 [89.03–92.1] 90.0 [88.93–91.52] NS
RDW (%) 12.75 [11.0–15.5] 12.4 [10.85–15.35] NS
Platelet (109/l) 288.0 [217.0–300.5] 288.0 [256.5–309.8] <0.05
MPV (fl) 8.65 [8.03–10.68] 8.80 [8.33–9.63] NS
WBC (109/l) 6.42 [5.91–7.4] 6.6 [6.0–7.34] NS
RBC, red blood cell count; MCV, mean cell volume; RDW, red cell distribution width; MPV, medium platelet volume;
WBC, white blood cell count; IQR, interquartile range; r, correlation index.
p < 0.05 was significant; NS, non-significant.
Table 4. Comparison of haematological parameters before and after atorvastatin treatment.
In all subjects, atorvastatin treatment was administered as either primary or secondary
prevention. By contrast, no significant changes of the selected haematological parameters were
observed after statin intervention, except for platelet count (Table 4). However, when applying
the correlation analysis, a strong association between the haematological parameters and
plasma lipids was evident at baseline and after 12 weeks of statin therapy (Tables 5 and 6). In
particular, in the subgroup of patients (n = 25) experiencing the greatest lipid-lowering effect,
as determined by the reduction of sdLDL-C, a statistically significant decline of MPV (p = 0.006)
was observed. A positive association between the levels of sdLDL-C and MPV in this cohort
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was clearly evident at baseline (r = 0.83, p < 0.001) and after therapy (r = 0.7, p < 0.001; Ta‐
ble 7). In addition, haemoglobin and platelet count appeared modified following a course of
statin treatment (p = 0.003, p = 0.03, respectively) in this subgroup of patient. Atorvastatin was
well-tolerated during the study. No serious adverse events were noted.
Baseline MPV RDW After treatment MPV RDW
Total cholesterol r = 0.04
NS
r = 0.10
NS
Total cholesterol r = −0.03
NS
r = 0.05
NS
LDL‐C r = 0.07
NS
r = 0.08
NS
LDL‐C r = −0.19
NS
r = 0.07
NS
HDL‐C r = −0.55
p < 0.001
r = −0.49
p < 0.001
HDL‐C r = −0.37
p < 0.05
r = −0.39
p < 0.05
TG r = 0.57
p < 0.001
r = 0.62
p < 0.001
TG r = 0.31
p < 0.05
r = 0.39
p < 0.05
LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; TG, triglycerides; MPV, medium platelet volume;
RDW, red cell distribution width; r, correlation index; NS, non-significant.
p < 0.05 was significant.
Table 5. Correlation between values of plasma lipids and haematological parameters at baseline and after treatment.
Baseline MPV RDW After treatment MPV RDW
LDL 1–2 r = −0.05
NS
r = −0.21
NS
LDL 1–2 r = 0.01
NS
r = 0.12
NS
sdLDL 3–7 r = 0.73
p < 0.001
r = 0.67
p < 0.001
sdLDL 3–7 r = 0.54
p < 0.001
r = 0.56
p < 0.001
IDL 1–3 r = −0.05
NS
r = 0.04
NS
IDL 1–3 r = −0.21
NS
r = 0.1
NS
apo_B r = 0.41
p < 0.05
r = 0.41
p < 0.05
apo B r = −0.03
NS
r = 0.26
NS
apo_A1 r = −0.36
p < 0.05
r = −0.24
NS
apo_A1 r = −0.19
NS
r = −0.26
NS
apo B/apo A1 r = 0.52
p < 0.001
r = 0.43
p < 0.05
apo B/apo_A1 r = 0.03
NS
r = 0.39
p < 0.05
AIP r = 0.61
p < 0.001
r = 0.65
p < 0.001
AIP r = 0.36
p < 0.05
r = 0.41
p < 0.05
LDL, low-density lipoprotein; sdLDL, small dense low-density lipoproteins; IDL, intermedium density lipoprotein;
apo_B, apolipoprotein B; apo_A1, apolipoprotein A1; AIP, atherogenic index of plasma; MPV, medium platelet volume;
RDW, red cell distribution width; r, correlation index; NS, non-significant.
p < 0.05 was significant.
Table 6. Correlation between lipoproteins, apolipoproteins, AIP and haematological parameters at baseline and after
treatment.
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Haematological parameters in the subgroup
(n n == 25)
Before treatment
Mean ± SD/Median
[IOR]
After treatment
Mean ± SD/Median [IOR]
p
RBC (1012/l) 4.46 ± 0.46 4.44 ± 0.46 NS
Haemoglobin (g/l) 145.8 ± 5.61 144.9 ± 5.81 p < 0.05
MCV (fl) 90.8 ± 2.15 90.21 ± 1.74 NS
RDW (%) 13.30 [12.2–15.85] 13.0 [11.5–15.8] NS
Platelet (109/l) 287.0 [194.0–298.0] 287.0 [209.0–306.0] p < 0.05
MPV (fl) 9.9 [8.4–10.9] 8.9 [8.45–9.85] p < 0.05
WBC (109/l) 6.34 [5.98–6.95] 6.6 [5.95–6.8] NS
RBC, red blood cell count; MCV, mean cell volume; RDW, red cell distribution width; MPV, medium platelet volume;
WBC, white blood cell count; IQR, interquartile range; r, correlation index; NS, non-significant.
p < 0.05 was significant.
Table 7. Comparison of haematological parameters before and after atorvastatin treatment.
4.5. Discussion
Over last decade, evidence from clinic trials indicates that broad-based treatment of dyslipi-
daemia can improve the event-free survival rate in people who already have clinical cardio-
vascular diseases [25]. However, assessment of atherogenesis requires the quantification small
dense lipoproteins both in patients with hyperlipoproteinaemia and normolipaemia. The
decrease in HDL-C level we observed requires further study. It also seems necessary to focus
on the changes of HDL subpopulations during lipid-lowering therapy [26]. A substantial
residual cardiovascular risk persists, despite best treatment efforts [27–29]. We observed a 35%
occurrence of hyperlipoproteinaemia LDL 1 and LDL 2 with non-atherogenic lipoprotein
profile phenotype A in our patients. LDL 1 and LDL 2 are less atherogenic or not atherogenic
at all and are responsible for the transport of cholesterol [30]. The presence of LDL 1 and LDL
2 in serum in the optimal concentration is essential for the normal function of endocrine organs
with steroidogenesis, but also for the formation of bile acids, vitamin D3, enzymes of lipid
metabolism and cell renewal of membrane structures. Within cells, cholesterol is important
precursor molecule for several biochemical pathways. There is necessary for their physiolog-
ical processes in the body [31]. It would be desirable for future studies to directly explain this
non-atherogenic hyperbetalipoproteinaemia LDL1,2 in hypercholesterolaemic subjects with
cardiometabolic diseases.
“Atherogenic normolipidaemia” after statin therapy is crucial, as this profile may increase
cardiovascular risk. However, the usefulness of searching for atherogenic lipoproteins in these
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patients requires further research. “Atherogenic normolipaemia” was not present in our
subjects, because we chose the patients for atorvastatin therapy according to the recommen-
dations for the treatment of dyslipoproteinaemia [32, 33]. However, a breakthrough in the stage
of subclinical atherosclerosis may not occur unless we are able to clearly quantify atherogenic
lipoproteins both in patients with hyperlipoproteinaemia and normolipaemia.
In our study, a correlation between apo B and lipoproteins was determined. Apo B was raised
not only in the presence of sdLDL 3–7 but also in the case of large LDL 1–2 particles. The only
protein component of LDL is a single molecule of apo B-100 per particle [34]. Apolipoprotein
B therefore cannot provide direct information about the density and size of particles in patients
in whom excess of sdLDL particles can be expected [33]. This is not common practice. There-
fore, the number of LDL particles could be more important in terms of risk than particle size
in itself as a better option for diagnosis of atherogenic particles. If further studies this option
confirmed, it seems that the easiest marker of atherogenicity could be the AIP [35]. Our results
show a significant change in LDL particle size (from larger and cholesterol-rich to smaller and
cholesterol-poor) after atorvastatin treatment. We wanted to point out the persistence of
“atherogenic normolipaemia” and hypercholesterolaemia in some patients irrespective of
statin therapy. Therefore, qualitative determination of lipoproteins after lipid-lowering
therapy was the aim of the study [36].
A lot of evidence support that statins have pleiotropic effects beyond their cholesterol-lowering
activity [37, 38]. For instance, statins modulate platelet function via direct interactions with
platelet membranes [39] or regulation of platelet signalling pathways [40]. Increased platelets
activity is crucial in pathophysiology of atherothrombosis. Recent reports showed that statins
involve the inhibition of calcium-dependent phospholipase A2 (cPLA2) [41], the activation of
nitric oxide synthase [42], and the accumulation of cAMP [43] in the anti-aggregation.
Treatment with atorvastatin or simvastatin also causes down-regulation of the expression of
CD36 and LOX-1, the reduction of platelet-associated oxidized LDL level [44] and thrombox-
ane A2 and B2 formation [39], and the inhibition of NADPH oxidase (Nox2) [45].
Although MPV is parameter of platelet size, it is considered as a marker of platelet reactivity
[46]. Sivri et al. reported that MPV significantly decreased after statin treatment for the
irrespective of cholesterol levels [47]. Recent trial indicates the effect of rosuvastatin on MPV
level although the changes were not correlated with the plasma lipids which may reflect
significant anti-platelet activation properties [48]. Similarly to previous study, the work with
atorvastatin has revealed possible relation of statin treatment and MPV [21]. We found that
there were no effect of 12 weeks atorvastatin therapy on MPV and RDW, but in the subgroup
of patients (n = 25) with the decrease in sdLDL-C after statin treatment, we have observed
significant reduction in MPV (Table 7).
The question of how we could decrease MPV has already been raised [49]. It has been revealed
that the lipid-lowering effect of statin therapy is not involved in inhibition of thrombus
formation in hypercholesterolaemic subjects. Previous finding suggests that other lipid-
independent effects of statins may contribute to their anti-aggregatory activity [50]. A limita-
tion of MPV, as a prognostic marker, is uncertain up-to-date as the relationship between platelet
size and cardiovascular risk is causative or is only a secondary effect.
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The RDW is a measurement of cell size distribution and is commonly requested test used for
variety of purposes, for instance to distinguish aneamias [51]. Recent work has revealed a
strong correlation between elevated RDW and the occurrence of fatal and nonfatal cardiovas-
cular events [52]. Complete blood count risk score including RDW was strongly associated
with all-cause mortality in the JUPITER study in primary populations initially free from
cardiovascular disease [53]. Recently, Lippi et al. [23] reported a significant association of
increased RDW and low HDL-C, as well as relation with high TG and high AIP involving 4874
unselected outpatients. An interventional study of 79 patients treated with atorvastatin (10–
80 mg) for 24-week period has not shown significant RDW changes [21]. It remains still
unknown which physiological process leads to previous outcomes, although inflammation has
been reported as possible cause [54]. Therefore, there might be a new and unpredictable
scenario in the clinical usefulness of RDW.
It has been suggested that cardiovascular risk may be more closely related to atherogenic
lipoprotein profile mostly represented by presence of sdLDL-C particles [55]. To our knowl-
edge, the present study was the first to analyse MPV and RDW in relation to concentration of
lipoprotein subfractions, especially with sdLDL-C. The main finding was that MPV and RDW
correlated with sdLDL-C and in subgroup of sdLDL-C lowering effect after treatment, indeed,
there was significant decrease in MPV value (Table 6). This may indicate that subjects with
more a pronounced lipid-lowering effect after statin treatment may benefit also from effects
beyond this well-known action. We have also observed that platelet count and haemoglobin
value have changed significantly after statin therapy in this subgroup. However, this finding
appears not to be clinically important.
The current study results suggest that MPV and RDW can play an important role not only in
hypercholesterolaemia but also interfering with atherogenic small dense lipoproteins.
Haematological parameters can be easily analysed at low cost and indices be new biomarkers
for atherosclerosis. The potential problems that may concern is that various studies revealed
the significance of MPV or RDW about the presence of various diseases and confounding
factors (obesity, smoking, arterial hypertension, inflammation diseases, pulmonary embolism,
etc.). Its clinical significance, however, remains largely difficult. There is still a need for further
prospective, multicentre studies with a large sample size to fully clarify the issue.
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